Mainz Biomed

Yahoo Finance • 4 months ago

DoctorBox Adds Mainz Biomed’s ColoAlert(R) to Its Portfolio

BERKELEY, Calif. and MAINZ, Germany, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company“), molecular genetics diagnostic company specializing in the early detection of cancer, today announce... Full story

Yahoo Finance • 4 months ago

Mainz Biomed and OncoVanguard8 Enter into Agreement to bring ColoAlert to South America

BERKELEY, Calif. and MAINZ, Germany, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company“), a molecular genetics diagnostic company specializing in the early detection of cancer, today announ... Full story

Yahoo Finance • 5 months ago

Mainz Biomed Showcases Innovative Cancer Detection Solutions at MEDICA 2025

BERKELEY, Calif. and MAINZ, Germany, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, is pleased t... Full story

Yahoo Finance • 5 months ago

Mainz Biomed to Attend the 38th Annual Meeting of the Gastroenterological Working Group of Rhineland-Palatinate (GARPS)

BERKELEY, Calif. and MAINZ, Germany, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, is pleased t... Full story

Yahoo Finance • 5 months ago

Mainz Biomed to Attend 2025 Maxim Growth Summit

BERKELEY, Calif. and MAINZ, Germany, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced to... Full story

Yahoo Finance • 6 months ago

Mainz Biomed Reports Topline Results from Feasibility Study of Biomarker Panel in Pancreatic Cancer Project

Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announces positive topline results from its feasibility study, examining a non-invasi... Full story

Yahoo Finance • 6 months ago

Mainz Biomed to Present the Future of Colorectal Cancer Screening at WEO CRC Screening Committee Meeting

BERKELEY, Calif. and MAINZ, Germany, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, is pleased... Full story

Yahoo Finance • 6 months ago

Mainz Biomed Announces Commercial Launch of ColoAlert® in Switzerland

BERKELEY, Calif. and MAINZ, Germany, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, is pleased... Full story

Yahoo Finance • 7 months ago

Mainz Biomed Announces Registration of ColoAlert in the United Kingdom

BERKELEY, Calif. and MAINZ, Germany, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announces t... Full story

Yahoo Finance • 8 months ago

Mainz Biomed Receives Swiss Regulatory Approval to Market ColoAlert®

BERKELEY, Calif. and MAINZ, Germany, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announces to... Full story

Yahoo Finance • 8 months ago

Mainz Biomed Announces Pricing of $3.0 Million Follow-On Offering of Ordinary Shares and Warrants

BERKELEY, Calif. and MAINZ, Germany, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, today announ... Full story

Yahoo Finance • 8 months ago

Mainz Biomed and CARE Conclude Cooperation Agreement for Joint Care Concept for Health Insurance Companies

BERKELEY, Calif. and MAINZ, Germany, July 23, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company“), a diagnostics company specializing in the early detection of cancer, today announced a collaboratio... Full story

Yahoo Finance • 9 months ago

Mainz Biomed Half Year 2025 Update: Accelerating FDA Pathway for NextGen Colorectal Cancer Screening and Expansion with Pancreatic Cancer Screening Acquisition

BERKELEY, Calif. and MAINZ, Germany, July 15, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, today review... Full story

Yahoo Finance • 9 months ago

Mainz Biomed Secures Public Funding to Advance Innovative Pancreatic Cancer Screening Test

BERKELEY, Calif. and MAINZ, Germany, June 25, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, is pleased t... Full story

Yahoo Finance • 10 months ago

Mainz Biomed Initiates Feasibility Study of Biomarker Panel in Pancreatic Cancer Project

BERKELEY, Calif. and MAINZ, Germany, June 10, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announces th... Full story

Yahoo Finance • 10 months ago

Will AI Empower the PR Industry or Create Endless Seas of Spam?

Communications pros are trying everything from generating pitch emails with AI to using facial recognition technology for more accurate survey results. Continue Reading View Comments... Full story

Yahoo Finance • 10 months ago

Mainz Biomed Announces Pricing of $4.0 Million Follow-On Offering of Ordinary Shares and Warrants

BERKELEY, Calif. and MAINZ, Germany, May 19, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, today announc... Full story

Yahoo Finance • 10 months ago

Mainz Biomed Announces Interim Read Out For Its eAArly DETECT 2 Clinical Study

Company intends to provide an interim read out by the end of summer 2025 Top-line results anticipated in Q4 2025; study on track to support U.S. pivotal trial initiation in 2026 BERKELEY, Calif. and MAINZ, Germany, May 16, 2025 (GLOBE... Full story

Yahoo Finance • 12 months ago

Mainz Biomed Reports 2024 Financial Results and Provides Corporate Update

Lab network revenue increased by 33% year over year, reflecting strong demand for ColoAlert® in Europe Operating loss decreased by 30% and net loss by 18%, driven by targeted cost reductions and a sharper strategic focus Strategic partne... Full story

Yahoo Finance • last year

Mainz Biomed Enrolls First Patient in Its eAArly DETECT 2 Clinical Study

2,000+ Average-Risk Patient Study Seeks to Confirm Mainz Biomed’s Industry-Leading Results in the Detection of Advanced Precancerous Lesions (APL) in Independent Samples Study is on Track to Report Top-Line Results in Fourth Quarter 2025... Full story